Preparation of asymmetric cyclic ureas through a monoacylated diamine intermediate
CA 2304513 A1 · Owner: The Dupont Merck Pharmaceutical Company · Inventors: Waltermire, Robert E.; Anzalone, Luigi; Stone, Benjamin R. P.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention concerns an improved process for the preparation of asymmetric cyclic ureas as well as intermediates in the preparation of asymmetric cyclic ureas of formula (VI): wherein: R7 is selected from the following: C1-C8 alkyl substituted with 0-3 R11; C2-C8 alkenyl substituted with 0-3 R11; C2-C8 alkynyl substituted with 0-3 R11; and a C3-C14 carbocyclic ring system substituted with 0-3 R11; R10 is C1-C10 alkyl benzyl, naphthylmethyl, 3,4-methylenedioxybenzyl or C1-C4 alkyl substituted with , phenyl wherein said phenyl is substituted with 0-3 R10a; G taken together along with the oxygen atoms to which G is attached forms a group selected from: …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 6, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 6, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 6, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.